m*3
2 楼
那就卖call卖put
：就在64-65之间来回震荡，被庄家压制得厉害啊！
【在 y**u 的大作中提到】
: 就在64-65之间来回震荡，被庄家压制得厉害啊！
：就在64-65之间来回震荡，被庄家压制得厉害啊！
【在 y**u 的大作中提到】
: 就在64-65之间来回震荡，被庄家压制得厉害啊！
w*9
3 楼
主要还是表现太差，消耗了无数买它的人的意志，没多少人感兴趣。跟mm没有多大关系。
这是个有名的臭股。
股市里机会那么多，干嘛顶上这个未来不大看好的股？forward p/e比p/e明显低。
这是个有名的臭股。
股市里机会那么多，干嘛顶上这个未来不大看好的股？forward p/e比p/e明显低。
N*d
4 楼
压制还是慢熊，难说！Insider最近都在大量出货。
话说回来，如果大家认为药厂研发就是杀老鼠，洗试管，再加上药物合成那么简单的话
，gild真是不错的选择
话说回来，如果大家认为药厂研发就是杀老鼠，洗试管，再加上药物合成那么简单的话
，gild真是不错的选择
P*u
5 楼
实业误国的道理你都不懂？
r*e
6 楼
Value investing is easily one of the most popular ways to find great stocks
in any market environment. After all, who wouldn’t want to find stocks that
are either flying under the radar and are compelling buys, or offer up
tantalizing discounts when compared to fair value?
One way to find these companies is by looking at several key metrics and
financial ratios, many of which are crucial in the value stock selection
process. Let’s put Gilead Sciences Inc. GILD stock into this equation and
find out if it is a good choice for value-oriented investors right now, or
if investors subscribing to this methodology should look elsewhere for top
picks:
PE Ratio
A key metric that value investors always look at is the Price to Earnings
Ratio, or PE for short. This shows us how much investors are willing to pay
for each dollar of earnings in a given stock, and is easily one of the most
popular financial ratios in the world. The best use of the PE ratio is to
compare the stock’s current PE ratio with: a) where this ratio has been in
the past; b) how it compares to the average for the industry/sector; and c)
how it compares to the market as a whole.
On this front, Gilead Sciences has a trailing twelve months PE ratio of 6.13
, as you can see in the chart below:
This level actually compares pretty favorably with the market at large, as
the PE for the S&P 500 compares in at about 20.32. If we focus on the stock
’s long-term PE trend, the current level puts Gilead Sciences’ current PE
ratio below its midpoint over the past five years, with the number remaining
stable over the past few months.
Further, the stock’s PE also compares favorably with the Zacks classified
Medical - Biomedical and Genetics sector’s trailing twelve months PE ratio,
which stands at 32.08. At the very least, this indicates that the stock is
relatively undervalued right now, compared to its peers.
We should also point out that Gilead Sciences has a forward PE ratio (price
relative to this year’s earnings) of just 8.25, which is tad higher than
the current level. So it is fair to expect an increase in the company’s
share price in the near term.
P/S Ratio
Another key metric to note is the Price/Sales ratio. This approach compares
a given stock’s price to its total sales, where a lower reading is
generally considered better. Some people like this metric more than other
value-focused ones because it looks at sales, something that is far harder
to manipulate with accounting tricks than earnings.
Right now, Gilead Sciences has a P/S ratio of about 2.94. This is a bit
lower than the S&P 500 average, which comes in at 3.14 right now. Also, as
we can see in the chart below, this is well below the highs for this stock
in particular over the past few years.
If anything, GILD is in the lower end of its range in the time period from a
P/S metric, suggesting some level of undervalued trading—at least compared
to historical norms.
Broad Value Outlook
In aggregate, Gilead Sciences currently has a Zacks Value Style Score of ‘A
’, putting it into the top 20% of all stocks we cover from this look. This
makes Gilead Sciences a solid choice for value investors.
What About the Stock Overall?
Though Gilead Sciences might be a good choice for value investors, there are
plenty of other factors to consider before investing in this name. In
particular, it is worth noting that the company has a Growth grade of ‘F’
and a Momentum score of ‘F’. This gives GILD a Zacks VGM score—or its
overarching fundamental grade—of ‘C’. (You can read more about the Zacks
Style Scores here >>)
Meanwhile, the company’s recent earnings estimates have been unfavorable.
The current quarter has seen five estimates go lower in the past sixty days,
while the full year estimate has seen three up and three down in the same
time period.
This has had a significant impact on the consensus estimate though as the
current quarter consensus estimate has decreased by 3.3% in the past two
months, while the full year estimate has declined almost 2.4%. You can see
the consensus estimate trend and recent price action for the stock in the
chart below:
Gilead Sciences, Inc. Price and Consensus
Gilead Sciences, Inc. Price and Consensus | Gilead Sciences, Inc. Quote
Despite the bearish analyst sentiments, the stock holds a Zacks Rank #3 (
Hold).
Bottom Line
Gilead Sciences is an inspired choice for value investors, as it is hard to
beat its incredible lineup of statistics on this front. However, with a
sluggish industry rank (among Bottom 36% of more than 250 industries) and a
Zacks Rank #3, it is hard to get too excited about this company overall. In
fact, over the past two years, the Zacks Medical - Biomedical and Genetics
industry has clearly underperformed the broader market, as you can see below:
So, value investors might want to wait for estimates and analyst sentiment
to turn around in this name first, but once that happens, this stock could
be a compelling pick.
in any market environment. After all, who wouldn’t want to find stocks that
are either flying under the radar and are compelling buys, or offer up
tantalizing discounts when compared to fair value?
One way to find these companies is by looking at several key metrics and
financial ratios, many of which are crucial in the value stock selection
process. Let’s put Gilead Sciences Inc. GILD stock into this equation and
find out if it is a good choice for value-oriented investors right now, or
if investors subscribing to this methodology should look elsewhere for top
picks:
PE Ratio
A key metric that value investors always look at is the Price to Earnings
Ratio, or PE for short. This shows us how much investors are willing to pay
for each dollar of earnings in a given stock, and is easily one of the most
popular financial ratios in the world. The best use of the PE ratio is to
compare the stock’s current PE ratio with: a) where this ratio has been in
the past; b) how it compares to the average for the industry/sector; and c)
how it compares to the market as a whole.
On this front, Gilead Sciences has a trailing twelve months PE ratio of 6.13
, as you can see in the chart below:
This level actually compares pretty favorably with the market at large, as
the PE for the S&P 500 compares in at about 20.32. If we focus on the stock
’s long-term PE trend, the current level puts Gilead Sciences’ current PE
ratio below its midpoint over the past five years, with the number remaining
stable over the past few months.
Further, the stock’s PE also compares favorably with the Zacks classified
Medical - Biomedical and Genetics sector’s trailing twelve months PE ratio,
which stands at 32.08. At the very least, this indicates that the stock is
relatively undervalued right now, compared to its peers.
We should also point out that Gilead Sciences has a forward PE ratio (price
relative to this year’s earnings) of just 8.25, which is tad higher than
the current level. So it is fair to expect an increase in the company’s
share price in the near term.
P/S Ratio
Another key metric to note is the Price/Sales ratio. This approach compares
a given stock’s price to its total sales, where a lower reading is
generally considered better. Some people like this metric more than other
value-focused ones because it looks at sales, something that is far harder
to manipulate with accounting tricks than earnings.
Right now, Gilead Sciences has a P/S ratio of about 2.94. This is a bit
lower than the S&P 500 average, which comes in at 3.14 right now. Also, as
we can see in the chart below, this is well below the highs for this stock
in particular over the past few years.
If anything, GILD is in the lower end of its range in the time period from a
P/S metric, suggesting some level of undervalued trading—at least compared
to historical norms.
Broad Value Outlook
In aggregate, Gilead Sciences currently has a Zacks Value Style Score of ‘A
’, putting it into the top 20% of all stocks we cover from this look. This
makes Gilead Sciences a solid choice for value investors.
What About the Stock Overall?
Though Gilead Sciences might be a good choice for value investors, there are
plenty of other factors to consider before investing in this name. In
particular, it is worth noting that the company has a Growth grade of ‘F’
and a Momentum score of ‘F’. This gives GILD a Zacks VGM score—or its
overarching fundamental grade—of ‘C’. (You can read more about the Zacks
Style Scores here >>)
Meanwhile, the company’s recent earnings estimates have been unfavorable.
The current quarter has seen five estimates go lower in the past sixty days,
while the full year estimate has seen three up and three down in the same
time period.
This has had a significant impact on the consensus estimate though as the
current quarter consensus estimate has decreased by 3.3% in the past two
months, while the full year estimate has declined almost 2.4%. You can see
the consensus estimate trend and recent price action for the stock in the
chart below:
Gilead Sciences, Inc. Price and Consensus
Gilead Sciences, Inc. Price and Consensus | Gilead Sciences, Inc. Quote
Despite the bearish analyst sentiments, the stock holds a Zacks Rank #3 (
Hold).
Bottom Line
Gilead Sciences is an inspired choice for value investors, as it is hard to
beat its incredible lineup of statistics on this front. However, with a
sluggish industry rank (among Bottom 36% of more than 250 industries) and a
Zacks Rank #3, it is hard to get too excited about this company overall. In
fact, over the past two years, the Zacks Medical - Biomedical and Genetics
industry has clearly underperformed the broader market, as you can see below:
So, value investors might want to wait for estimates and analyst sentiment
to turn around in this name first, but once that happens, this stock could
be a compelling pick.
r*e
7 楼
在现在这个inflated market，GILD算个不错的选择，还有中大型油股
w*9
8 楼
过去6个月insiders卖了254万股
float： 1.3B
short interest恰好是1%,非常低
过去三次报earnings，两次missed
过去三个月对未来的预期还在小降
上个季度Quarterly Revenue Growth (yoy) -16.50%
上个季度Quarterly Earnings Growth (yoy) -24.20%
预期今年的每个季度revenue平均下降近20%
Current Qtr. earning预期 -31.50%
Next Qtr. earning预期 -28.00%
Current Year earning 预期 -29.10%
Next Year earning预期 -9.40%
因此forward p/e： 8.63，虽然p/e： 6.78
68元多的时候就有人推荐。我就说这个股不要去碰。现在大盘已经有疲软迹象。它可能
会被index funds带得更低。
过去两年有无数的潜水员在上面等着逃逸。
float： 1.3B
short interest恰好是1%,非常低
过去三次报earnings，两次missed
过去三个月对未来的预期还在小降
上个季度Quarterly Revenue Growth (yoy) -16.50%
上个季度Quarterly Earnings Growth (yoy) -24.20%
预期今年的每个季度revenue平均下降近20%
Current Qtr. earning预期 -31.50%
Next Qtr. earning预期 -28.00%
Current Year earning 预期 -29.10%
Next Year earning预期 -9.40%
因此forward p/e： 8.63，虽然p/e： 6.78
68元多的时候就有人推荐。我就说这个股不要去碰。现在大盘已经有疲软迹象。它可能
会被index funds带得更低。
过去两年有无数的潜水员在上面等着逃逸。
w*9
9 楼
股票是forward looking
要想买是可以，等它的销售和盈利真正有了下降明显减缓再说
我估计至少要有几个月，那时股市也应该修正了一些，买入的价格应该会比现在明显低。
要想买是可以，等它的销售和盈利真正有了下降明显减缓再说
我估计至少要有几个月，那时股市也应该修正了一些，买入的价格应该会比现在明显低。
r*e
10 楼
如果没有这些问题，pe肯定在20以上了。不觉得gild会继续大降。而且，gild可以画一
个饼：买公司。这样的新闻一出来，就可以卖了。上次我65进的，pop到70的时候就因
为这样的传闻
特斯拉和马鬃画了这么大的饼，gild也可以画一画
[在 wewill2009 (daluobe) 的大作中提到：]
:过去6个月insiders卖了254万股
:float： 1.3B
:short interest恰好是1%,非常低
:过去三次报earnings，两次missed
:过去三个月对未来的预期还在小降
:上个季度Quarterly Revenue Growth (yoy) -16.50%
:上个季度Quarterly Earnings Growth (yoy) -24.20%
:预期今年的每个季度revenue平均下降近20%
:Current Qtr. earning预期 -31.50%
:Next Qtr. earning预期 -28.00%
:..........
个饼：买公司。这样的新闻一出来，就可以卖了。上次我65进的，pop到70的时候就因
为这样的传闻
特斯拉和马鬃画了这么大的饼，gild也可以画一画
[在 wewill2009 (daluobe) 的大作中提到：]
:过去6个月insiders卖了254万股
:float： 1.3B
:short interest恰好是1%,非常低
:过去三次报earnings，两次missed
:过去三个月对未来的预期还在小降
:上个季度Quarterly Revenue Growth (yoy) -16.50%
:上个季度Quarterly Earnings Growth (yoy) -24.20%
:预期今年的每个季度revenue平均下降近20%
:Current Qtr. earning预期 -31.50%
:Next Qtr. earning预期 -28.00%
:..........
w*9
11 楼
明年p/e是9
后年p/e可能就是10了
未来几个月的大趋势是下降，降到60以下的可能性非常大
去赌那种暂时的pop还不如去玩别的更可靠的机会
【在 r*****e 的大作中提到】
: 如果没有这些问题，pe肯定在20以上了。不觉得gild会继续大降。而且，gild可以画一
: 个饼：买公司。这样的新闻一出来，就可以卖了。上次我65进的，pop到70的时候就因
: 为这样的传闻
: 特斯拉和马鬃画了这么大的饼，gild也可以画一画
: [在 wewill2009 (daluobe) 的大作中提到：]
: :过去6个月insiders卖了254万股
: :float： 1.3B
: :short interest恰好是1%,非常低
: :过去三次报earnings，两次missed
: :过去三个月对未来的预期还在小降
w*9
12 楼
简而言之，这是个正在大步走下坡路的公司。
宁可卖agn这种未来p/e是13但是在上升的公司，也不要买未来p/e是9在走大下坡路的公
司。
宁可卖agn这种未来p/e是13但是在上升的公司，也不要买未来p/e是9在走大下坡路的公
司。
a*d
13 楼
你们买药股看不看pipeline还是怎么研究公司啊
w*9
14 楼
就看未来预期就行了。
看pipeline是很难说的。好像大部分小药股都到了phase 3了最后没成大气还是
crushing down。
【在 a******d 的大作中提到】
: 你们买药股看不看pipeline还是怎么研究公司啊
d*1
15 楼
希望ceo快快走人，又不出新药，又不买出新药的公司，坐在钞票上，你是吃饭呢还是
吃钞票呢：）。。
吃钞票呢：）。。
相关阅读
哪位熊军的勇士把牛军的果旗拔了？明天是牛熊分界线难道牛市来了？FASfunds和bonds有什么不同?今天对JKS来说是非常重要的一天气愤!花街的骗子们!usb有毛病阿。。downgrade baidu。。这些天，股市走的都很boring啊。[通知] Stock 举办博彩：周四大盘(DOW)涨跌美国第二轮金融危机正在临近(zz)（买FAZ吧）俺的CRM很结实10000保卫战已经打响了。The 27.9% MoM existing home plunge is overrated呼唤隆巴多NND，非路边的特警真废物股市杀多一触即发大家觉得apple还有机会上270么？股市杀空一触即发谈股论金(Stockcafeteria)俱乐部目前非成员可以浏览